Potentially Dangerous Side Effects of Drug Discussed by Invokana Lawsuit Plaintiffs Following FDA Safety Warning

April 25, 2016 – – TheProductLawyers.com reports on multiple lawsuits filed against Janssen Pharmaceuticals (a subdivision of Johnson & Johnson corporation) in connection with their new-generation drug, Invokana which is aimed at treating type-2 diabetes. Invokana was the first of a group of similar drugs released to treat diabetes which are known as SGLT2 class inhibitors. Multiple adverse event reports made to FDA have led to an initial group of impacted plaintiffs filing recent lawsuits. It is expected that other legal suits will follow. Litigation is based on the allegation that patients who have used Invokana consequently developed the potentially life-threatening condition, diabetic ketoacidosis.

Diabetic ketoacidosis is a condition in which the patient’s bloodstream retains a surplus of toxic acid at dangerous levels. It can develop in as little as 24-hours, and affected patients can lapse into comatose states or even die if the deadly condition remains undiagnosed and untreated.

One of the first lawsuits filed in the U.S. against Invokana manufacturers took place on December 15th, 2015. The complaint was filed in the U.S. District Court for the Southern District of Alabama under case number 1:15-cv-00636. Additional court document details indicate that the plaintiff involved reported commencing usage of Invokana in December of 2014, and shortly after that ceased ingesting the drug due to the confirmed onset of diabetic ketoacidosis.

Aa extremely similar lawsuit was filed just days prior on December 10th, 2015. This suit is filed under case number 15-12-00653 in the Court of Common Pleas in Philadelphia, Pennsylvania. Further details of this suit note that the male plaintiff reports starting intake of Invokana in November of 2014, and ceased usage of the drug when diagnosed with diabetic ketoacidosis within three months.

Diabetic ketoacidosis linked to Invokana use was the focus of a recent U.S. Food and Drug Administration safety communication. The FDA has also required Invokana manufacturer Janssen to make correct adjustments to the drug’s warning label to sufficiently warn patients of the risk of diabetic ketoacidosis as well as urinary tract infections. The agency has warned those taking the drug that they should be alert for any signs of the development of diabetic ketoacidosis. Onset symptoms include nausea and vomiting, breathing difficulty, excess fatigue, and abdominal pain.

For more information about the Invokana lawsuits, or this press release, please contact TheProductLawyers.com on 888-997-3792.

###

Contact TheProductLawyers.com:

Banville Law
888-997-3792
info@banvillelaw.com
165 West End Ave #1h,
New York, NY 10023

ReleaseID: 60009508